Vertex Pharmaceuticals Inc.
Cowen & Co. analyst David Stone said the Cambridge, Mass., company's HIV protease inhibitor,
, is potentially superior to Merck's drug.
In 28-day primate studies, VX-478 was
Continue reading with a two-week free trial.